---
title: Effects of Nutritional Products on Blood Glucose in Subjects With Type 2 Diabetes
nct_id: NCT00753181
overall_status: COMPLETED
phase: PHASE3
sponsor: Abbott Nutrition
study_type: INTERVENTIONAL
primary_condition: Diabetes Mellitus, Type 2
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00753181.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00753181"
ct_last_update_post_date: 2009-04-27
last_seen_at: "2026-05-12T07:16:22.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effects of Nutritional Products on Blood Glucose in Subjects With Type 2 Diabetes

**NCT ID:** [NCT00753181](https://clinicaltrials.gov/study/NCT00753181)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** Abbott Nutrition
- **Conditions:** Diabetes Mellitus, Type 2
- **Start Date:** 2008-08
- **Completion Date:** 2009-03
- **CT.gov Last Update:** 2009-04-27

## Brief Summary

To evaluate average daily blood glucose in subjects with type 2 diabetes following a Meal Plan including Diabetes-Specific products compared to average daily blood glucose in subjects following their usual diet.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. type 2 diabetes
2. HbA1c \>6.5% and \<11.0%
3. male/non-pregnant, non-lactating female, at least 6 months postpartum
4. if female of childbearing potential, practicing method of birth control
5. Body Mass Index \> 18.5 kg/m2 and \< 43.0 kg/m2.
6. weight stable for past two months
7. if on anti-hypertensive, lipid-lowering, thyroid medication or hormone therapy, dosage constant for at least two months

Exclusion Criteria:

1. uses injected medications (e.g., insulin, exenatide) for glucose control.
2. history of diabetic ketoacidosis
3. current infection ; inpatient surgery, or corticosteroid treatment in the last 3 months or antibiotics in the last 3 weeks
4. active malignancy
5. states he/she has had a significant cardiovascular event \< 12 weeks prior to study entry or history of congestive heart failure in the last 12 months.
6. end stage organ failure
7. active metabolic, hepatic, or gastrointestinal disease that may interfere with nutrient absorption, distribution, metabolism, or excretion (such as gastroparesis), excluding diabetes.
8. chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV.
9. use of herbals, dietary supplements, or medications, other than allowed medications, during past four weeks that could profoundly affect blood glucose.
10. symptomatic in response to blood collection prior to enrollment into this study.
11. clotting or bleeding disorders.
12. non-typical eating pattern
13. is currently using diabetes-specific nutritional product(s)defined as more than one eating occasion per week.
14. engages in strenuous exercise five or more times per week.
```

## Arms

- **A1** (EXPERIMENTAL) — Diabetes Meal Plan with Experimental Diabetes-Specific nutritional shake
- **A2** (ACTIVE_COMPARATOR) — Usual diet
- **A3** (EXPERIMENTAL) — Diabetes Meal Plan with Experimental Diabetes-Specific Nutritional Shake, diabetes specific Cereal, and diabetes specific snack bars.

## Interventions

- **Nutritional Formula** (OTHER) — nutritional shake daily
- **Usual diet** (OTHER) — usual dietary habits
- **Diabetes Meal Plan with experimental diabetes-specific nutritional shake, diabetes specific cereal, and diabetes specific snack bars.** (OTHER) — nutritional shake, diabetes specific cereal and diabetes snack bar daily

## Primary Outcomes

- **Average daily blood glucose level** _(time frame: 11 days)_

## Secondary Outcomes

- **Percentage of time in specified glucose ranges; Glycemic excursions; Change in plasma glucose, insulin, free fatty acids, triglycerides, 1,5-anhydroglucitol, and fructosamine; Dietary intake variables** _(time frame: 11 days)_

## Locations (2)

- Provident Clinical Research, Bloomington, Indiana, United States
- Radiant Research, Cincinnati, Ohio, United States

## Recent Field Changes (last 30 days)

- `locations.radiant research|cincinnati|ohio|united states` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.provident clinical research|bloomington|indiana|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00753181.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00753181*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*